MET and plasma cell myeloma: Tivantinib, a Met inhibitor, reduced tumor burden and inhibited myeloma-induced bone disease in vivo; a Met antagonist inhibited HGF-induced MM cell proliferation, survival, migration, and adhesion, and reversed HGF-induced inhibition of osteoblastogenesis [29,52].